All Transactions - Bryan, Garnier & Co

Our transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Nicox’ Euronext Paris EUR 10 million Follow-on Offering & Warrants issuance

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing

Bryan, Garnier & Co acts as Sole Financial Advisor to Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, on its first €21 million closing of its oversubscribed Fundraising

Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign on the sale of its CRO activities to Elyan Partners for €100m and the concomitant spin-off of its Biotech/AI activities

Bryan, Garnier & Co acts as Sole Global Coordinator & Sole Bookrunner on GeNeuro EUR 7.7 million Follow-On Offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Aelis Farma’s Euronext Paris EUR 25m Initial Public Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to clinical-stage biologics company BiosanaPharma on its global strategic partnership with Alvotech

Bryan, Garnier & Co acts as Sole Financial Advisor to MNH on the sale of AKLIA to Hoppen

Bryan, Garnier & Co is proud to act as Joint Bookrunner to Cell Impact on its SEK 349m Rights Issue

Bryan, Garnier & Co acts as Sole Financial Advisor to Wandercraft on its $45 million Fundraising

Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering of shares and warrants

Bryan, Garnier & Co acts as Lead Joint Bookrunner to leading German Specialty Pharmaceuticals provider Medios AG on its EUR 93 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Enapter Follow-On Offering of EUR 30m

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq & Euronext Paris USD 102m Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on its acquisition of STAR Teams, and as Joint Global Coordinator on subsequent SEK 250 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to Cleerly on its USD 43 million Series B Fundraising

Bryan, Garnier & Co acts as Joint Bookrunner on BICO’s SEK 2 billion Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner on Heidelberg Pharma’s EUR 20 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to FCDE on its acquisition of a majority stake in Didactic alongside its management team

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Abivax’s EUR 85 million Follow-on Offering & Convertible Bonds Issuance

Bryan, Garnier & Co advises Halma on its acquisition of PeriGen

Bryan, Garnier & Co acts as Joint Bookrunner to Valneva on its USD 108 million Nasdaq Initial Public Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Laboratoires Majorelle on the sale of a majority stake to EW Healthcare Partners

Bryan, Garnier & Co acts as Sole Financial Advisor to French telemedicine leader Qare on its acquisition by European digital health provider HealthHero

Bryan, Garnier & Co acts as European Lead Manager to Humanigen on its USD 100.4 million Marketed Follow-on Offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to GenSight on its EUR 30 million Follow-on Offering

GenSight_2021_website_tombstone

Bryan, Garnier & Co acts as Sole Financial Advisor to Medisys on its merger with Cityzen

Medisys_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Basilea Pharmaceutica on its CHF 46 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Ginolis Ltd on the sale of the company to BICO AB

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to MedinCell on its EUR 30 million Follow-on Offering

Medincell_website_tombstone

Bryan, Garnier & Co helps Zealand Pharma raise DKK 749 million from the global capital markets via an accelerated bookbuild

Zealand_Pharma_tombstone

Bryan, Garnier & Co acts as Sole Financial Advisor to Lifco on its acquisition of ContacEZ

Lifco_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering

Nicox_website_tombstone

Bryan, Garnier & Co acts as Sole Financial Advisor to Calliditas Therapeutics on its acquisition of Genkyotex for €88 million

Calliditas_website_tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner to Abivax on its EUR 28 million Follow-on Offering

Abivax_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunner to GenSight on its EUR 25 million Follow-on Offering

Tombstone_gensight

Bryan, Garnier & Co acts as Joint Bookrunner to Targovax on its NOK 75 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to INNOTHERA Group on its acquisition of Gibaud

Innothera_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunner on Sensorion’s EUR 31 million Follow-on Offering with top tier US and European biotech specialists and institutional investors

website_tombstone_2

Bryan, Garnier & Co acts as European Lead Manager to Humanigen on its USD 78 million Follow-on Offering

tombstone_humanigen_78200000_dollars

Bryan, Garnier & Co acts as Co-manager to BioNTech on its USD511.5 million upsized Publicly-marketed Follow-on Offering

BioNTech_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Carbios on its EUR 37 million upsized Follow-on Offering

Carbios website tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator on a EUR 7.3 million Rights Issue for medtech company Pixium Vision

Pixium_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on MedinCell’s Follow-on with top-tier European biotech specialists and institutional investors

Medincell_website_tombstone

Bryan, Garnier & Co acts as Sole M&A and Strategic Advisor to BlueBee on its sale to Illumina

Bluebee_website_tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner on Lysogene’s Private Placement with top tier US and European Investors

Lysogene_website_tombstone_2

Bryan Garnier & Co acts as Joint Bookrunner and Joint Broker to AIM-listed 4D Pharma on its GBP 22 million equity Fund Raising

4Dpharma_website_tombstone

Bryan, Garnier & Co acts as Sole Financial Advisor to Biocodex on its Acquisition of Laboratoires IPRAD

Biocodex_website_tombstone_2

Bryan, Garnier & Co acts as Sole Bookrunner on GeNeuro EUR17.5 million Private Placement

GeNeuro_website_tombstone

Bryan, Garnier & Co advised Lee Biosolution on its sale to Medix Biochemica